Trial of Parkinson's And Zoledronic Acid (TOPAZ)

Project Summary: This study is a randomized placebo-controlled trial of a single infusion of zoledronic acid-5 mg for the prevention of fractures in 3500 men and women aged 65 years and older with Parkinson’s disease willing and able to continue in follow-up for up to 5 years.

Study Website

PI(s): Steven Cummings, MD

PaTH Protocol PI(s):

  • Susan Greenspan, MD – University of Pittsburgh
  • Mihai Sandulescu, MD – Geisinger Health System

Purpose: To test the efficacy of Zoledronic acid compared with placebo to reduce the risk of clinical fractures in Parkinson’s disease patients.

Goal(s): To reduce clinical fractures in Parkinson’s disease patients.

Study Design: This is a multi-center, site-less clinical trial that will utilize telemedicine and nurse home visits to interact with participants.

PaTH Partners:

  • The University of Pittsburgh
  • Geisinger Health System

Sponsor: NIA/NIH

Coordinating Center: San Francisco Coordinating Center

How to Participate: Participants interested in joining the study can visit topazstudy.org to complete the electronic informed consent and a health survey.

PaTH Network Logo
Twitter Logo Facebook Logo LinkedIn Logo YouTube Logo

Copyright 2016 | PaTH Network